BriovaRx

About BriovaRx

BriovaRx operates as a specialty pharmacy and home infusion service provider, concentrating on patients with complex and chronic conditions requiring specialized medication and administration. The company was acquired by OptumRx, the pharmacy care services unit of UnitedHealth Group, and now operates under the Optum Specialty Pharmacy and Optum Infusion Pharmacy brands. This integration followed a series of strategic acquisitions by Optum, including BriovaRx's former parent company, Catamaran, in 2015, to build out its specialty pharmacy capabilities.

The business model is centered on providing comprehensive medication management and clinical support for conditions such as oncology, immunology, and other complex diseases. This involves more than dispensing medication; it includes a holistic, patient-centric approach with services like medical reimbursement management, insurance verification, and individualized treatment plans. Revenue is generated by providing these specialized medications and services to patients who typically pay through private insurance or are part of government health plans like Medicare and Medicaid. The firm serves a nationwide client base, partnering with payers, providers, and pharmaceutical manufacturers to manage the distribution and administration of high-cost specialty drugs.

BriovaRx's service offerings include home infusion therapies, such as intravenous antibiotic therapy, chemotherapy, and total parenteral nutrition, alongside specialty pharmacy services for self-administered medications. A key feature was the BriovaLive program, which offered patients private video consultations with specialty pharmacists to improve understanding and adherence to complex treatment regimens. The company provides medication and nursing support in patients' homes or at its infusion suites, which are designed to offer a more convenient and less costly alternative to hospital-based infusions. By integrating with Optum, the company has expanded its access to limited distribution drugs and a larger payer network, aiming to reduce costs and improve health outcomes for patients with significant healthcare needs.